Highbridge Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-6,700
Closed -$474K 635
2018
Q2
$474K Buy
6,700
+3,600
+116% +$254K 0.01% 599
2018
Q1
$234K Sell
3,100
-2,000
-39% -$159K ﹤0.01% 986
2017
Q4
$364K Sell
5,100
-3,700
-42% -$281K 0.01% 1112
2017
Q3
$712K Buy
+8,800
New +$673K 0.01% 748
2016
Q4
Sell
-13,100
Closed -$1.04M 1375
2016
Q3
$1.04M Buy
13,100
+8,900
+212% +$723K 0.02% 558
2016
Q2
$350K Sell
4,200
-1,100
-21% -$97.6K 0.01% 991
2016
Q1
$486K Buy
+5,300
New +$478K 0.01% 988
2014
Q2
Sell
-5,000
Closed -$354K 1146
2014
Q1
$354K Buy
+5,000
New +$392K ﹤0.01% 794
2013
Q3
Sell
-13,300
Closed -$683K 1373
2013
Q2
$683K Buy
+13,300
New +$693K 0.01% 786

Other funds holding GILD

Highbridge Capital Management's GILD Position: Q4 2018 in Review

Highbridge Capital Management sold out of Gilead Sciences (GILD) in Q4 2018, closing a stake of 31,541 shares — an estimated $2.44M sold.

Highbridge Capital Management first reported a position in GILD in Q2 2013 and held it in 18 quarters. The position peaked at $72.4M in Q4 2015. 1,496 funds tracked by Wall St. Rank hold GILD as of Q4 2018.

  • Highbridge Capital Management reported no remaining Gilead Sciences position as of Q4 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 31,541 Gilead Sciences shares in Q4 2018, an estimated $2.44M.
  • Highbridge Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 18 quarters.
  • Highbridge Capital Management's Gilead Sciences position peaked at $72.4M in Q4 2015.
  • 1,496 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2018.

Based on Highbridge Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.